Abstract: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
Type:
Application
Filed:
December 14, 2015
Publication date:
December 28, 2017
Inventors:
Yvonne Y. CHEN, Eugenia ZAH, Michael C. JENSEN
Abstract: The invention relates to a method for determination of the frequency of regulatory T-cells in samples obtained from human blood and to methods for the preparation of compositions comprising predetermined amount of regulatory T-cells. The invention is based on the conception that a large fraction of regulatory T-cells present in human peripheral blood do not express detectable amounts of Foxp3, the master transcription factor used for identification of regulatory T-cells, as a result of cytokine deprivation outside of the tissue context.
Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
Type:
Application
Filed:
July 13, 2017
Publication date:
December 28, 2017
Applicants:
Kite Pharma, Inc., United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
Abstract: The present invention concerns therapeutic formulations containing active agents, such bioactive cell populations, and methods of making and using the same.
Type:
Application
Filed:
July 6, 2017
Publication date:
December 28, 2017
Inventors:
Joydeep Basu, Richard Payne, Neil F. Robbins, Oluwatoyin A. Knight, Deepak Jain, Craig R. Halberstadt, Monica A. Serban
Abstract: The present invention relates to a composition including stem cell-derived microvesicles as an active ingredient for promoting neurogenesis. The stem cell-derived microvesicles according to the present invention can promote neurogenesis and migration of nerves and also promote angiogenesis in vascular endothelial cells, and thus can be usefully used in treatment of neurological damage.
Type:
Application
Filed:
July 14, 2017
Publication date:
December 28, 2017
Inventors:
Oh Young Bang, Gyeong Joon Moon, Yeon Hee Cho, Suk Jae Kim, Dong Hee Kim, Ji Hee Sung
Abstract: The present disclosure relates to methods of inducing tolerance to lung allograft transplantation. These methods comprise increasing suppressor CD8+ T cells and/or suppressing deleterious CD8+ and CD4+ T cells.
Type:
Application
Filed:
September 1, 2017
Publication date:
December 28, 2017
Inventors:
Alexander Sasha Krupnick, Daniel Kreisel, Andrew Gelman
Abstract: Disclosed are compositions comprising a non-homogenized chorionic matrix, a homogenized amniotic matrix and a homogenized UC (UC) matrix, wherein the non-homogenized chorionic matrix comprises viable cells. Disclosed are methods of making the compositions disclosed herein comprising preparing a non-homogenized chorionic matrix, preparing a homogenized amniotic matrix, preparing a homogenized UC matrix, and combining the non-homogenized chorionic matrix, the non-homogenized chorionic matrix, and the homogenized UC matrix. Disclosed are methods of treating a tissue injury or chronic pain comprising administering any of the disclosed compositions to an area of a subject comprising a tissue injury.
Type:
Application
Filed:
June 23, 2017
Publication date:
December 28, 2017
Inventors:
Steven Michael Sinclair, Alla Danilkovitch, Malathi Sathyamoorthy, Jin-Qiang Kuang, Sandeep Dhall, Yishan Liu, Anthony John Melchiorri, Matthew Robert Moorman, Mena Schiano Lo Moriello, Anne Allgood Lerch
Abstract: Methods for treating radiation or chemical injury are described that comprise administering to a subject a therapeutically effective amount of adherent stromal cells. Methods of preparing adherent stromal cells and pharmaceutical compositions comprising the cells are also described.
Abstract: Disclosed herein are pluripotent stem cells cultured with one or more peptide and methods of isolating said stem cells. Also disclosed are methods of targeting the stem cells to a desired region or area within an organism. Also disclosed are methods of using the isolated stem cells for the improvement of fertility, for the promotion of hair growth, for the treatment or prevention of skin conditions, for the treatment or improvement of bone disorders, for the treatment of malignancies, and for the treatment of neurological disorders.
Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.
Type:
Application
Filed:
September 8, 2017
Publication date:
December 28, 2017
Inventors:
Lee M. Kaplan, Alice P. Liou, Peter J. Turnbaugh, Jason L. Harris
Abstract: This document relates to materials and methods for treating infections (e.g., ear infections and/or skin infections). For example, methods and materials for using a probiotic fermentation product to treat a veterinary animal (e.g., non-human mammal) having an infection and/or a complication associated with an infection (e.g., hearing loss caused by an ear infection) are provided.
Type:
Application
Filed:
June 28, 2017
Publication date:
December 28, 2017
Inventors:
Kathryn J. Petrucci, Sarah E. Royer Köster
Abstract: The inventions disclosed herein relate to the findings that L. reuteri bacteria isolated from dog saliva is capable of modulating a subject's body weight. In certain aspects, the inventions disclosed herein relate to the findings that L. reuteri species isolated from dog saliva elevates a subject's oxytocin levels in blood plasma and surprisingly, the killed (lysed) bacteria was sufficient to achieve the observed effects.
Abstract: Methods for treating and preventing dysbiosis in a subject suffering from or susceptible to gastrointestinal disorders are described. The methods comprises administering a hyperimmunized egg product to the subject, wherein the egg product is obtained from a hyperimmunized avian, optionally in combination with an additional compound such as a probiotic and/or nutrient source.
Abstract: The present invention provides a novel lactic acid bacterium having antioxidant and anti-aging functions and a dementia alleviation effect, and more specifically, provides Lactobacillus pentosus var. plantarum C29 KCCM11291P and Lactobacillus curvatus C3 KCCM430009. In addition, the present invention provides an antioxidant and anti-aging pharmaceutical composition and a dietary supplement containing the Lactobacillus pentosus var. plantarum C29 KCCM11291P or Lactobacillus curvatus C3 KCCM430009 of the present invention as an active ingredient, and a composition for preventing or treating dementia and a dietary supplement for preventing or alleviating dementia, containing Lactobacillus pentosus var. plantarum C29 KCCM11291P or Lactobacillus curvatus C3 KCCM430009 as an active ingredient. Additionally, the present invention provides a composition for preventing or treating dementia, containg a fermentation composition, as an active ingredient, fermented by Lactobacullus pentosus var.
Type:
Application
Filed:
July 5, 2017
Publication date:
December 28, 2017
Inventors:
DONG-HYUN KIM, MYUNG JOO HAN, IL-HOON JUNG, MYUNG-AH JUNG
Abstract: The invention relates to the pharmaceutical or non-pharmaceutical use of an effective amount of spirulina and/or of an extract/extracts of spirulina for improving the bioavailability of orally administered curcumin in humans or animals. The invention also includes pharmaceutical or non-pharmaceutical preparations including spirulina and/or extracts of spirulina containing curcumin having improved bioavailability.
Abstract: The subject matter of the instant invention relates to methods of compounding compositions comprising bacteriophage effective for treating bacterial infections, including but not limited to, multidrug resistant bacterial infections. The invention also relates to compositions, bacterial diversity sets, and phage libraries prepared according to the methods of the instant invention.
Type:
Application
Filed:
June 20, 2017
Publication date:
December 28, 2017
Applicant:
United States of America as Represented by the Secretary of the Navy
Inventors:
James M Regeimbal, Biswajit Biswas, Matthew S. Henry
Abstract: To increase the therapeutic potential of these oncolytic viruses based on a 24 base pair deletion in the viral E1 A gene (D24), a conditionally replicating adenovirus targeting multiple receptors upregulated on tumors was generated by incorporating an Ad5/3 fiber with a carboxyl terminus RGD ligand. The virus displayed full cytopathic effect in tumor lines assayed at low titers with improved cytotoxicity over Ad5-RGD D24, Ad5/3 D24 and an HSV oncolytic virus. The virus was further engineered to deliver immunotherapeutic agents such as GMCSF while maintaining enhanced heterogenic oncolysis.
Abstract: Methods for treatment and compositions are provided for increasing the health of humans, livestock, and companion animals. More particularly, dietary supplements (also referred to as PPA (prebiotic, probiotic, antibodies) compositions) for treating humans, livestock, and companion animals, and methods for making and using them for treatment of various conditions are disclosed.
Type:
Application
Filed:
June 23, 2017
Publication date:
December 28, 2017
Inventors:
Valentino Grant, Dayna J. Campbell, George D. Ranglin
Abstract: The present invention provides the use of a fungal immunomodulatory protein (FIP) in manufacturing a medicament for inhibiting hepatocyte growth factor receptor (HGFR) activity in a cell, and for treating HGFR-associated cancer.
Abstract: The present invention relates a use of Antrodia cinnamomea composition, consisting of 50-99% (W/W) of Antrodia cinnamomea solid-state cultivated mycelium water/alcohol extracts and 1-50% (W/W) of cut-log wood cultivated fruiting body water/alcohol extracts, in the preparation of auxiliary agents for chemotherapy. The Antrodia cinnamomea composition of the present invention has proven effects on improving the anti-cancer effects when combined with chemotherapy drugs, and reducing the toxicity and side effects caused by chemotherapy treatments. The composition of present invention can be applied to use as an auxiliary for anti-cancer agents.
Abstract: The present invention relates to a traditional Chinese medicine composition for regulating immunity and preparation method thereof, characterized in that the composition comprises raw materials such as Radix Panacis Quinquefolii, Ganoderma, fermented Cordyceps sinensis powder, Flos Rosae Rugosae, and Rhizoma Anemarrhenae and is prepared into various conventional pharmaceutical formulations through processes such as pulverization, water decoction and alcohol extraction. The traditional Chinese medicine composition is effective in preventing and treating allergic diseases, hepatitis B and AIDS, elevating leukocytes, preventing and treating radiation injury, reducing toxic and side effects resulting from radiotherapy and chemotherapy, improving the male sexual function, enhancing immunity of the human body and alleviating physical fatigue.
Type:
Application
Filed:
September 7, 2017
Publication date:
December 28, 2017
Inventors:
Hongguang Zhong, Minzhi Yi, Jianzhong Lu
Abstract: The present invention relates to a pharmaceutical composition and a food composition for preventing or ameliorating degenerative neurological disease comprising Poria cocos peel extract for preventing, or treating neurodegenerative disorders. Poria cocos peel extract which is the active ingredients contained in the composition of the present invention, has a memory ameliorating activity through inhibiting of acetylcholine esterase and a neuroprotective effect and neuron protection by inhibiting the formation of beta amyloid and tau phosphorylation and promoting NGF production. Thus, the present invention may be useful as a pharmaceutical composition for preventing or treating degenerative neurological diseases, or as a health food for the above purpose.
Type:
Application
Filed:
December 3, 2015
Publication date:
December 28, 2017
Inventors:
Sang Zin CHOI, Mi Won SOHN, Hyo Sang GO, Ja Young RYU, Jin Seok JEONG, Song Hyen CHOI, Eun Jin KIM, Young Woong CHO, So Young KIM
Abstract: The invention relates to an anti-inflammatory agent comprising coniferous resin acids and to pharmaceutical formulations containing said agent for use in treating and preventing sterile inflammation.
Abstract: The present invention relates to a pharmaceutical composition when used for inhibiting a herpesviridae infection and/or providing relief from a herpesviridae infection in a subject. The composition includes an effective amount of an extract from a plant in the Asteraceae family.
Abstract: Provided is a method for extracting and refining alkaloids from ipecac, comprising: (1) grinding ipecac, adding acidic methanol/ethanol solution for extraction, obtaining an extraction solution A, concentrating under a reduced pressure, and obtaining a concentrated solution B; (2) using reversed-phase polymer filler J for adsorption, and performing desorption by washing with water, collecting a washing solution C, eluting with an alcoholic solution E and collecting a desorption solution D; (3) injecting the washing solution C and the desorption solution D into a preparative high performance liquid chromatograph for separation and purification respectively, to collect a solution G, and a solution H and a solution I respectively; and (4) concentrating the solutions G, H and I, which are then subjected to reversed-phase polymer filler K for adsorption respectively; eluting them respectively after adsorption with an alcoholic solution F; concentrating obtained eluates to dryness; and then performing vacuum drying
Abstract: The present invention provides a pharmaceutical composition or a food composition containing combined extracts comprising Schisandrae fructus, Eucommiae cortex and Lycii fructus as active ingredients for preventing or treating metabolic bone diseases. The composition of the present invention does not have side effects as it is a substance derived from natural sources; is effective on osteogenesis in ovariectomized mice; increases the bone content and the bone formation index of serum in real animal model; and reduces the bone resorption index so as to be useful for preventing or treating metabolic bone diseases.
Abstract: Embodiments described herein provide for uses of grape products, such as Chardonnay grape products and grape seed flour, for use in promoting a healthy liver, promoting healthy fat content in a liver, for treating or preventing NAFLD, and other embodiments and uses as described herein.
Type:
Application
Filed:
December 18, 2015
Publication date:
December 28, 2017
Inventors:
Torey James Arvik, Hyunsook Kim, Wallace H. Yokoyama, Scott R. Forsberg
Abstract: The present invention relates to a chemical and pharmaceutical technology, and in particular to a STAT3 and ERK signal pathway inhibitor and a use thereof. The present invention provides a STAT3 and ERK signal pathway inhibitor. The inhibitor mainly consists of a mogroside and/or an analog thereof. The mogroside and the analog thereof inhibit the phosphorylation of a transcription factor STAT3 and the phosphorylation of an ERK. The method for preparing the mogroside and the analog has the characteristics of simpleness, strong operability and high purity of products. The present invention furtherprovides a use of the STAT3 and ERK signal pathway inhibitor in the preparation of drugs for treating tumors, which realizes the purposes of inhibiting the proliferation of cancer cells and promoting the apoptosis of cancer cells and has a very good inhibition effect on cancers.
Abstract: The present invention provides a pharmaceutical composition containing a cancer antigen peptide for treatment and prevention of angiogenic diseases.
Type:
Application
Filed:
December 10, 2015
Publication date:
December 28, 2017
Applicant:
International Institute of Cancer Immunology, Inc.
Abstract: The present disclosure provides methods to treat conditions, including cancer, using compounds that can target resistant cancer cells. The compounds can be used to sensitize resistant cancer cells or decrease the proliferation of cells. The compounds can target proteins in the DNA damage repair pathway leading to a decrease in DNA damage repair in target cells.
Abstract: Disclosed are methods for treating, preventing and alleviating obesity, fatty liver syndrome, diabetes, one or more metabolic syndrome conditions or complications and/or cancer comprising administering an effective amount of ostreolysin, its functionally related variant, or an extract or mushroom extract comprising the same to subjects in need thereof.
Abstract: The invention relates to a proteasome inhibitor for use for treating and/or preventing a disorder related to an accumulation of a non-degraded abnormal protein, particularly a premature ageing disorder. The invention also relates to the use of proteasome inhibitors for attenuating physiological ageing. The invention also relates to the use of proteasome inhibitors in the treatment and/or prevention of age-related disorders and their metabolic consequences. The invention also relates to the dermato logical, dermo cosmetic or cosmetic use of a proteasome inhibitor for preventing and/or attenuating skin ageing. The invention also relates to the use of proteasome inhibitors in the treatment of cancer.
Type:
Application
Filed:
January 14, 2016
Publication date:
December 28, 2017
Inventors:
Nicolas Levy, Pierre Cau, Annachiara De Sandre-Giovannoli, Karim Harhouri, Sophie Perrin, Claire Navarro, Aymeric Chartier, Martine Simonelig
Abstract: The embodiments herein relate to the combination of herbal and probiotic (optionally with prebiotic) treatment for chronic liver diseases to be novel and more effective. Embodiments herein relate to a composition comprising a probiotic and a medicinal herb (and optionally a prebiotic), wherein the composition is effective in treating a liver disease such as inflammation of liver in a novel approach to disease management. The combination of a prebiotic, a probiotic and a medicinal herb constitutes a symbiotic formulation. Clinical and animal data exists to show efficacy of these combinations. The ingredients, as well as the categories, in the combination are novel. Using a combination of twelve herbs and three probiotics, a highly efficacious and novel supplement is disclosed herein. Embodiments of the compositions herein could further include homeopathic drugs and an active pharmaceutical ingredient such as an allopathic drug.
Type:
Application
Filed:
November 15, 2016
Publication date:
December 28, 2017
Inventors:
Neil Shivraj DAVEY, Neil RUSTGI, Priya PURI, Sonya Raj DAVEY, Vinod RUSTGI
Abstract: Embodiments herein generally relate to methods, compositions and uses of CaMKII inhibitors. Other embodiments relate to methods, compositions and uses of agents that target CaMKII. Yet further embodiments relate to compositions, methods and uses of CaMKIIN-derived molecules and other CaMKII inhibitor molecules that inhibit autonomous CaMKII activity. In accordance with these embodiments, compositions that inhibit autonomous CaMKII activity may be used for treating conditions causing neuronal cell death, for treating cancer or for treating neurodegenerative disorders.
Abstract: An example of the composition incudes at least one amino acid sequence from the octarepeat region of hemin that is modified by substituting at least one proline (P) residue in the amino acid sequence. The composition is effective to bind with hemin and for treating hemorrhagic injury.
Abstract: The present invention provides a method of treating cancer with an integrin-binding-Fc fusion protein alone or in combination with IL-2 and/or an immune checkpoint inhibitor. The invention also provides composition for use in such methods.
Abstract: Disclosed herein is a method of promoting sustained survival, sustained regeneration, in a lesioned mature neuron, sustained compensatory outgrowth in a neuron, or combinations thereof. The method comprises contacting the lesioned mature neuron with an effective amount of an inhibitor of PTEN and an effective amount of an inhibitor of SOCS3 to thereby promote survival and/or regeneration and/or compensatory outgrowth of the neuron. Therapeutic methods of treatment of a subject with a neuronal lesion by administration of a therapeutically effective amount of an inhibitor of PTEN and a therapeutically effective amount of an inhibitor of SOCS3, are also disclosed, as are pharmaceutical compositions and devices for use in the methods.
Abstract: Disclosed are uses of neuregulin in the preparation of medicines for preventing, treating or delaying ventricular arrhythmia of a human being, and pharmaceutical preparations that comprise the neuregulin and are used for preventing, treating or delaying the ventricular arrhythmia.
Abstract: The method of tissue transplantation involving recellularizing of a donor organ with the utilization of the recipient's cytokines collected from the recipient's blood plasma at less than systemic pressure, and at the temperature greater than freezing and less than normal systemic temperature of the recipient's blood. Specifically, a method of harvesting a platelet-derived growth factors from platelet rich plasma (PRP), the growth factors having increased weight.
Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.
Type:
Application
Filed:
July 10, 2017
Publication date:
December 28, 2017
Inventors:
HUNTINGTON POTTER, TIMOTHY BOYD, HEATHER SEVEY LAWRENCE JIM
Abstract: The present invention encompasses compositions and methods useful to treat or prevent Clostridium difficile antibiotic-associated colitis through administration of IL-25 and/or downstream cytokines IL-13, IL-4, and IL-5. It is disclosed herein that IL-25 expression is decreased during antibiotic treatment and during bacterial infection and that treatment with IL-25 protein is protective during infection. It is further disclosed herein the unexpected result that IL-25 treatment protects against C. difficile-associated mortality and morbidity. The present application further describes an unexpected result regarding eosinophils and their role in combating infection and their relationship to the effectiveness of IL-25.
Type:
Application
Filed:
October 7, 2015
Publication date:
December 28, 2017
Applicant:
University of Virginia Patent Foundation
Abstract: The invention provides compositions and methods for modulating the immunostimulatory properties and/or anti-inflammatory properties of IL-10. The present invention provides scIL-10 polypeptides of Formula 1. The polypeptides of the invention are optionally linked to a fusion partner. The polypeptides of Formula 1 are referred to herein as “scIL-10” polypeptides and comprise an amino acid sequence arrangement from N-terminus to C-terminus in accordance with Formula 1: (first monomer subunit)-LINKER-(second monomer subunit)?? Formula 1 wherein the first monomer subunit, the second monomer subunit or both the first and second monomer subunits may be independently selected from: an unsubstituted IL-10 monomer subunit; or a substituted IL-10 monomer subunit comprising at least one amino acid substitution; and wherein LINKER is any amino acid linker of at least 1-100 amino acids in length.
Type:
Application
Filed:
June 22, 2017
Publication date:
December 28, 2017
Inventors:
Demetri T. Moustakas, Mark N. Namchuk, Heather C. Losey, Juan C. Alvarez
Abstract: A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.
Type:
Application
Filed:
June 2, 2017
Publication date:
December 28, 2017
Inventors:
Thomas R Alessi, Ryan D. Mercer, Catherine M. Rohloff, Bing Yang
Abstract: A composition in aqueous solution includes insulin and at least one substituted anionic compound chosen from substituted anionic compounds consisting of a backbone formed from a discrete number u of between 1 and 8 (1?u?8) of identical or different saccharide units, linked via identical or different glycoside bonds, the saccharide units being chosen from the group consisting of hexoses, in cyclic form or in open reduced form, said compound comprising partially substituted carboxyl functional groups, the unsubstituted carboxyl functional groups being salifiable. A pharmaceutical formulation including the composition is also set forth.
Type:
Application
Filed:
May 31, 2017
Publication date:
December 28, 2017
Applicant:
ADOCIA
Inventors:
Olivier SOULA, Gerard SOULA, Emmanuel DAUTY, Richard CHARVET
Abstract: The subject matter of this invention is directed towards chemically and thermodynamically stable single-chain insulin (SCI) analogues that are resistant to deamidation and fibrillation. The invention further discloses improved methods for the recombinant expression, purification and refolding of SCI.
Type:
Application
Filed:
August 29, 2017
Publication date:
December 28, 2017
Inventors:
Michael H.B. Stowell, Yanyu Peng, Mikhail Plam